EN DE
Watch Eyepoint Pharmaceuticals Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Eyepoint Pharmaceuticals Inc (EYPT) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Eyepoint Pharmaceuticals Inc stock $0.35, price $0.40, that is 13.4% below the price, quality 23 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

EP Eyepoint Pharmaceuticals Inc logo Thin data Nov 10, 2026

Eyepoint Pharmaceuticals Inc

EYPT · US
Expensive, weak quality

Our calculation puts a fair price 13% below what the stock costs today.

Low debt
Insiders bought $52,258 (6M) · sold $73,174
Fair value $0.3463 · Overvalued
Quality 23/100
Weak Growth (revenue 5y −1.8 %/yr in USD)
Negative free cash flow
Trails peers (2/8)
Narrow moat 11/100 · thin data
Thin data
Estimate
Watch Eyepoint Pharmaceuticals Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$29.71 $0.3500 Fair Value $0.3463 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $0.3500 – $29.71 · fair‑value band $0.2597 – $0.4329 · the $0.4000 price screens above the $0.3463 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Eyepoint Pharmaceuticals in your weekly email

Every Wednesday you see whether Eyepoint Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.

Show moreShow less

Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases.

The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.

Stock analysis

Eyepoint Pharmaceuticals Inc (EYPT) currently trades at $0.4000, while our estimate is $0.3463, 13% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.2597 (bear) to $0.4329 (bull), the price of $0.4000 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 23/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Eyepoint Pharmaceuticals Inc reported revenue of $31.4M in FY2025 versus $36.9M in FY2021, a compound −4.0%/yr. Reported net income was −$232M in FY2025.

Key figures

Market cap $34.6M Micro · P/S ratio 12.4 · EPS (TTM) $−3.75 · Return on equity −149% · Return on assets (EBIT) −39.8% (5-year average) · Operating margin −19,207% · Revenue growth (YoY) −90.5% · Free cash flow −$243M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 11 out of 100 (low confidence).

What moves the price

The share trades about 98% below its 52-week high and 14% above its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −13%, EYPT screens richer than that median.

Fair Value

Bear $0.2597 Fair Value $0.3463 Bull $0.4329
Price $0.4000 · Downside -13.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 23/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 3
How much profit the company makes from its sales and capital
Quality Growth 22
Are margins and returns getting better?
Cashflow 12
Do the profits arrive as real cash?
Financial strength 72
Debt, balance sheet and risk of trouble
Investment 18
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 8
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director bought shares worth $52,258, on Aug 18, 2026. Over the same period, one person sold shares worth $73,174.

  • BuyKaren L. ZaderejDirector10,600 shares at $4.93$52,258Aug 18, 2026
  • SaleRamiro RibeiroChief Medical Officer6× since Nov 11, 2025: 57,453 shares, avg. $16.52$948,956Jun 30, 202610b5-1 plan
  • BuyJay S. DukerPresident and CEO, Director1,500 shares at $13.15$19,725Mar 16, 2026
  • SaleCormorant Asset Management, LPFormer 10% Owner60,000 shares at $15.70$942,000Dec 4, 2025
  • SaleNancy LurkerDirector2× since Nov 26, 2025: 10,000 shares, avg. $15.10$150,988Dec 4, 202510b5-1 plan

Plus 4 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−27.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.8%
Start year 2020 (pandemic). Over 10 years: +1.7% a year
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−108.3% (2020) → −776.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

EYPT screens overvalued: fair value 13% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Eyepoint Pharmaceuticals Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 23 · Bottom 25%
Fair Value upside −13.4% · Above median
Profitability
Return on assets −63.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −90.5% · Bottom 25%
Balance sheet
Debt / equity 0.10× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.11× · Cheapest 25%
P/S (12 months) 12.42× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)15 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)95 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs EYPT
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs EYPT
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs EYPT
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs EYPT
argenx SE ARGX $971.55 $908.40 −7% vs EYPT
CSL Limited CSL A$201.68 A$181.40 −10% vs EYPT
Moderna, Inc MRNA $250.83 $158.70 −37% vs EYPT
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs EYPT
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs EYPT
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs EYPT

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Eyepoint Pharmaceuticals Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Eyepoint Pharmaceuticals Inc Fair Value". https://www.fairvalue-calculator.com/stock/EYPT

Frequently asked questions

Is Eyepoint Pharmaceuticals Inc (EYPT) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $0.3463 versus a price of $0.4000, about 13% lower (overvalued).
What is the fair value of EYPT?
Our estimate for Eyepoint Pharmaceuticals Inc is $0.3463 (as of Nov 10, 2026), built from audited fundamentals. The current price: $0.4000.
What is the quality score of EYPT?
Eyepoint Pharmaceuticals Inc has a Quality Score of 23/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Eyepoint Pharmaceuticals Inc (EYPT)?
Our calculated price target is the estimate of $0.3463 (as of Nov 10, 2026). Cautious scenario $0.2597, optimistic scenario $0.4329. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Eyepoint Pharmaceuticals Inc stock forecast for 2026?
Our estimate puts fair value at $0.3463, about 13% lower versus a price of $0.4000 (overvalued). Cautious scenario $0.2597, optimistic scenario $0.4329. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Eyepoint Pharmaceuticals Inc (EYPT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Eyepoint Pharmaceuticals Inc it is $0.3463 per share (as of Nov 10, 2026), against a price of $0.4000.
Is Eyepoint Pharmaceuticals Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, EYPT trades above its calculated fair value: price $0.4000, fair value $0.3463, a gap of about −13% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EYPT?
No. The price is what the market pays today ($0.4000); the fair value is what the company's own numbers justify ($0.3463). For Eyepoint Pharmaceuticals Inc the two are $0.0537 per share apart. That gap is exactly why we show both numbers side by side.
How much is Eyepoint Pharmaceuticals Inc worth?
The market values Eyepoint Pharmaceuticals Inc at about $34.6M (market capitalisation, as of Nov 10, 2026). Per share that is $0.4000; our models calculate a fair value of $0.3463 per share.
What do the bullish and bearish scenarios say about EYPT?
Our models span a range for Eyepoint Pharmaceuticals Inc: cautious scenario $0.2597, base $0.3463, optimistic $0.4329 per share (as of Nov 10, 2026, price $0.4000). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Eyepoint Pharmaceuticals Inc (EYPT)?
Balance-sheet figures for Eyepoint Pharmaceuticals Inc (as of Nov 10, 2026): return on equity −148.7%, debt of 0.10 per unit of equity. They feed the Quality Score of 23/100, which measures business quality independently of the share price.
How far is EYPT from its 52-week high?
Eyepoint Pharmaceuticals Inc trades at $0.4000, about 98% below its 52-week high of $18.85 and 14% above the low of $0.3500 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $0.3463 is for.
Which stocks are comparable to Eyepoint Pharmaceuticals Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Eyepoint Pharmaceuticals Inc stock attractive at the current price?
The data as of Nov 10, 2026: price $0.4000, calculated fair value $0.3463 (−13%), Quality Score 23/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Eyepoint Pharmaceuticals Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Eyepoint Pharmaceuticals Inc (EYPT)?
The closing price on Nov 10, 2026 was $0.4000. Our estimate is $0.3463, about 13% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Eyepoint Pharmaceuticals Inc right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Eyepoint Pharmaceuticals Inc

How large is the market capitalisation of Eyepoint Pharmaceuticals Inc (EYPT)?
The market capitalisation of Eyepoint Pharmaceuticals Inc is $34.6M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Eyepoint Pharmaceuticals Inc (EYPT)?
The price-to-sales ratio of Eyepoint Pharmaceuticals Inc is 12.4 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Eyepoint Pharmaceuticals Inc (EYPT)?
Earnings per share at Eyepoint Pharmaceuticals Inc are $−3.75. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Eyepoint Pharmaceuticals Inc (EYPT)?
The return on equity (ROE) of Eyepoint Pharmaceuticals Inc is −149% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Eyepoint Pharmaceuticals Inc (EYPT)?
On an EBIT basis the return on assets of Eyepoint Pharmaceuticals Inc is −39.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Eyepoint Pharmaceuticals Inc (EYPT)?
The operating margin of Eyepoint Pharmaceuticals Inc is −19,207% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Eyepoint Pharmaceuticals Inc (EYPT)?
Revenue at Eyepoint Pharmaceuticals Inc is growing −90.5% versus a year earlier (3y avg −8.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Eyepoint Pharmaceuticals Inc (EYPT) generate?
The free cash flow of Eyepoint Pharmaceuticals Inc is −$243M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Eyepoint Pharmaceuticals Inc (EYPT) hold?
Eyepoint Pharmaceuticals Inc holds more cash than debt, $81.0M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Eyepoint Pharmaceuticals Inc in the live analysis

One click puts Eyepoint Pharmaceuticals Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.